A local oncologist talks about a group that’s at higher risk of dying from breast cancer. View the video at KSAT.com
Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team
Sharon Wilks joined NEXT Oncology’s phase I clinical investigation team, bringing more than 30 years of research and clinical experience to the practice. View the full article at the Cancer Letter
NEXT Oncology Partners with Spanish Hospital System to Open Two Phase I Clinical Trial Centers
NEXT Oncology entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain. View the full article at Cancer Letter
Quirónsalud launches two new phase I clinical trial units in Madrid and Barcelona
El Grupo Quirónsalud ha puesto en marcha dos nuevas unidades de ensayos clínicos de fase I gracias al acuerdo alcanzado con NEXT Oncology, empresa estadounidense líder en el desarrollo de este tipo de ensayos creará en Europa. The Quirónsalud Group has launched two new phase I clinical trial units thanks to the agreement reached with NEXT Oncology, a leading American company in the development of …
Next Oncology Expends Phase I Program with Virginia Cancer Specialists Partnership
For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a medical oncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, director of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new partnership and how …
Medical World News® Inside the Practice: CancerNetwork® With Anthony W. Tolcher, MD, and Alexander I. Spira, MD, PhD, on Expand Access to Phase 1 Cancer Trials
For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a mMedical oOncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, Medical Oncologist and dDirector of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new …
What the New KRAS Inhibitor Means for Lung Cancer
Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field — moderator Vinay Prasad, MD, …
Genomic Test in Lung Cancer: Waiting Is the Hardest Part
— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well …
What Did We Learn From IMpower010 in Resectable NSCLC
At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three leaders in the field — moderator Vinay Prasad, MD, of the University …
YourSA Best Oncologist: NEXT Oncology
Dr. Anthony Tolcher’s dedication to medical advancements and innovative approaches at NEXT Oncology has earned the practice Best Oncologist in San Antonio in the 2021 Readers’ Choice Awards. NEXT Oncology has made strides in patient care, especially over the past year. As a Phase 1 research center, patient safety is critical. Patients on clinical trials are faced with even greater …